NFKB1 and metabolic dysfunction-associated steatohepatitis: ANO1 can participate in inflammatory responses through the NF‐κB signalling pathway,27 and ANO1 overexpression enhances the activation of the TLR4–NF‐κB signalling pathway, which enhances the inflammatory response in the liver, especially in NASH.27